Press releases
The latest milestones from ValamAi’s platform, pipeline and team.
ValamAi Announces Grant of First Patent for “Signal Peptide With Heterologous Protein”
ValamAi has received a Notice of Allowance for its first Composition of Matter patent covering its innovative signal peptide technology — a significant milestone in expanding its intellectual property portfolio globally.
ValamAi Highlights Founding Science Behind VMB-100, Published in Molecular Therapy – Nucleic Acids (2023)
Peer-reviewed preclinical data underpinning VMB-100 (Antony JS et al., 2023) demonstrate accelerated functional recovery and tissue regeneration, supporting clinical development in stress urinary incontinence.
ValamAi Welcomes Prof. Friedrich Metzger to its Scientific Advisory Board
Prof. Metzger, co-inventor of VMB-100 and former lead of preclinical development for Risdiplam (Evrysdi™) at Roche, brings more than 18 years of pharma and biotech R&D experience.
ValamAi Announces Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence
Regulators have cleared ValamAi’s Investigational New Drug application for VMB-100, clearing the way for a planned Phase IIa clinical study.